BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:Pacific Standard Time
X-LIC-LOCATION:America/Los_Angeles
BEGIN:STANDARD
DTSTART:20231105T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11
TZNAME:PST
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20240310T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3
TZNAME:PDT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:2022 Annual Meeting by the ºÃÉ«ÏÈÉú\n\nTi
 tle: Industry Therapeutic Update from argenx: Innovation in Anti-AChR Ant
 ibody Positive gMG Treatment for Adults: Clinical Data of VYVGARTâ„¢ (efgar
 tigimod alfa-fcab) in the Pivotal ADAPT Trial\n\nAccess URL: https://www.
 aan.com/msa/Public/Events/GetEventURL/14724\n\nLearn More About This Even
 t: /msa/Public/Events/Details/14724
DTEND;TZID=Pacific Standard Time:20220405T220000
DTSTAMP:20250503T161042Z
DTSTART;TZID=Pacific Standard Time:20220405T190000
LOCATION:/msa/Public/Events/GetEventURL/14724
SEQUENCE:0
SUMMARY:AAN: Industry Therapeutic Update from argenx: Innovation in Anti-A
 ChR Antibody Positive gMG Treatment for Adults: Clinical Data of VYVGARTâ„¢
  (efgartigimod alfa-fcab) in the Pivotal ADAPT Trial
UID:e643f7ed-d0af-43ac-b6e5-ab979c7a5d27
END:VEVENT
END:VCALEND